Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
491.34
+11.16 (+2.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
8,693,049
Open
482.50
Bid (Size)
488.80 (40)
Ask (Size)
491.00 (80)
Prev. Close
480.18
Today's Range
482.20 - 503.89
52wk Range
362.50 - 507.92
Shares Outstanding
259,428,394
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
↗
Today 6:20 EDT
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.
Via
The Motley Fool
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.
↗
June 23, 2026
The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.
Via
MarketBeat
Topics
ETFs
Performance
YTD
+8.7%
+8.7%
1 Month
+12.4%
+12.4%
3 Month
+13.5%
+13.5%
6 Month
+6.1%
+6.1%
1 Year
+10.8%
+10.8%
More News
Read More
Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals
↗
June 23, 2026
Via
Chartmill
The Best Stocks to Invest $1,000 in Right Now
↗
June 22, 2026
Via
The Motley Fool
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals
↗
June 01, 2026
Via
Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout
↗
May 28, 2026
Via
Chartmill
3 of Wall Street’s Favorite Stocks to Consider Right Now
June 22, 2026
Via
StockStory
2 Reasons to Like VRTX (and 1 Not So Much)
June 22, 2026
Via
StockStory
If I Had to Start Over With $1,000 in Stocks Today, Here's Exactly What I'd Buy
↗
June 20, 2026
Via
The Motley Fool
Topics
Intellectual Property
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.
↗
June 20, 2026
Via
The Motley Fool
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year
↗
June 18, 2026
Via
The Motley Fool
3 Market-Beating Stocks Worth Investigating
June 18, 2026
Via
StockStory
The Best Biotech Stocks to Buy in 2026
↗
June 17, 2026
Via
The Motley Fool
Topics
ETFs
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
June 11, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
↗
June 08, 2026
Via
The Motley Fool
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
↗
June 08, 2026
Via
The Motley Fool
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
June 05, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
The Best Stocks to Invest $500 in Right Now
↗
June 04, 2026
Via
The Motley Fool
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
June 03, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
June 01, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges
May 29, 2026
Via
StockStory
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
↗
May 25, 2026
Via
The Motley Fool
Which S&P500 stocks are moving on Tuesday?
↗
May 12, 2026
Via
Chartmill
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
↗
May 11, 2026
Via
The Motley Fool
Vertex to Participate in Upcoming May Investor Conferences
May 11, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Frequently Asked Questions
Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 491.34
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 06/26/26 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 127.47B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 127B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.